title: Companies Claim to Fame and their scientific challenges in vaccine development.
abstract: Although basic scientific immunological knowledge is the foundation for the development of novel vaccination approaches, beyond proof of concept in animal models, translational scientific immunological efforts are obligatory for successful development of a vaccine for use in humans. Translational technology is developed/used by biotechnology companies to generate better, safer or cheaper vaccines. Their proprietary position and/or proprietary technology are the basis of services that they offer to other companies or for products that they develop themselves. Some of the translational challenges are described in this review. In addition, a number of novel technologies developed by several biotechnology companies in The Netherlands are described. This document however, is far from complete and highlights only a small part of it.
authors.affiliation: Bioceros BV, Utrecht, The Netherlands. l.boon@bioceros.com
authors.forename: Louis
authors.initials: L
authors.lastname: Boon
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D001709:Biotechnology / Q000379:methods* / Q000639:trends; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D009980:Influenza A virus / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control; D017780:Malaria Vaccines / Q000276:immunology*; D016778:Malaria, Falciparum / Q000276:immunology / Q000517:prevention & control; D009426:Netherlands; D010963:Plasmodium falciparum / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D017780:Malaria Vaccines; D014765:Viral Vaccines